OKUR reports financial results, advancing leads
OnKure Therapeutics reported Q2 2026 results with $176M cash runway until 2029, while advancing PI3Kα pan-mutant inhibitor pipeline candidates for IND submissions in 1H 2027.
View filing at SEC.gov →1 most recent filing and news item mentioning OKUR. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/OKUR/news?limit=20"
Pull OKUR filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayOnKure Therapeutics reported Q2 2026 results with $176M cash runway until 2029, while advancing PI3Kα pan-mutant inhibitor pipeline candidates for IND submissions in 1H 2027.
View filing at SEC.gov →